Evidence map›Paper›PMID 41972812›Full record

ArticleEpilepsia2026

Redefining the treatment pathway for medication-resistant epilepsy in the cenobamate era: Surgical obviation or surgical delay.

Wesley T Kerr, Katherine N McFarlane

Abstract read
In one paragraph

Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wesley T KerrDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-5546-5951
Katherine N McFarlaneDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0009-0000-0365-813X

Funding

Feasibility of machine learning to improve the diagnostic odyssey for functional seizuresK23NS135134 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Wesley Thomas Kim Kerr · 2025 to 2026
$448k
Biohaven PharmaceuticalsNINDS NIH HHS K23 NS135134NINDS NIH HHS K23NS135134SK Life ScienceUniversity of Pittsburgh
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41972812
PMCPMC13361025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.